An interventional study of Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy and Transperitoneal lymphadenectomy in Endometrial Cancer, Lymphadenectomy and Sentinel Lymph Node Biopsy, sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Endometrial Neoplasms with a site in Turkey — 14 open to participants now, 18 under way, 4 of them phase 3. Endometrial Neoplasms · Turkey.
Among the 46 studies in Endometrial Neoplasms with a site in Turkey, this one is the 28th largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 3 of the 17 other live ones, and was the 35th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →14 of the 46 studies in Endometrial Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Mahmut Yassa · Sites in Turkey
Ages 18–90 · Women only
Cukurova University · Sites in Turkey
Women only
BioNTech SE · Sites in Turkey, United States, Argentina and 24 more countries
Ages 18+ · Women only
Dokuz Eylul University · Sites in Turkey
Ages 18–75 · Women only
Daiichi Sankyo · Sites in Turkey, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2011; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 52 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 100 across the 33 interventional studies, 106 across the 13 observational. Of the 23 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 46 have an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital is the lead sponsor of 59 studies on the registry; 24 are open to participants now.
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital has 2 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Endometrial Neoplasms with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT06163963Istanbul UniversitySentinel Lymph Node in Early-Stage Endometrium Cancer | 2027-09 |
| NCT05489211AstraZenecaStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies in Endometrial Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare two types of lymphadenectomy (transperitoneal vs. paracervical) during the lymphadenectomy phase of endometrial cancer staging surgery performed using V-NOTES, a new and advanced technique. This study seeks to optimize the V-NOTES technique for endometrial cancer staging. This randomized, prospective, controlled study will include patients diagnosed with endometrial cancer via histology, following physical examination and imaging, and who are electively scheduled for the V-NOTES endometrial cancer staging procedure. Patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group. The parameters related with surgical and functional outcomes will be compared in both groups.
Surgical staging is often the primary management strategy for endometrial cancer. Sentinel lymph node (SLN) procedures are considered an alternative standard of care in the treatment of significant uterus-confined malignancy. Both accurately estimate nodal status and reduce the surgical morbidity associated with complete lymphadenectomy. Laparoscopic surgery for endometrial cancer has been associated with equal or better quality of life, less blood loss and similar cancer-related outcomes. A new innovation, natural orifice transluminal endoscopic surgery (NOTES), has been developed to further reduce morbidity and scarring associated with laparoscopic surgery. NOTES utilizes the natural orifices of the human body for access to the peritoneal cavity when performing endoscopic surgery.
However, there is no standardization in vNOTES SLN mapping and lymph tracers are diverse. Many procedures and tracers have been reported, such as intra- or retroperitoneal surgery, a range of vaginal surgeries, SLN exposure method, and indocyanine green or methylene blue injection, and they lack comparative studies. This study will evaluate feasibility and surgical outcomes by comparing transvaginal paracervical and transperitoneal mapping in vNOTES hysterectomy with SLN procedure in endometrial cancer.
The study is an observational study with a prospective design. It will be implemented in a single institution, specifically Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.
Between March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping.
According to inclusion and exclusion criteria, the patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group.
Surgical Procedure of transvaginal paracervical sentinel lymphadenectomy group:
All patients(26) will receive V-NOTES with transvaginal paracervical sentinel lymph node (SLN) mapping followed by V-NOTES hysterectomy and bilateral salpingo-oophorectomy (BSO).
Transperitoneal sentinel lenfadenectomy group's Surgical Procedure:
All patients (26) will receive vNOTES hysterectomy with bilateral salpingo-oophorectomy (BSO) followed by transperitoneal vNOTES sentinel lymph node (SLN) mapping.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Selection and Data Collection This study will be implemented in a single institution, Diyarbakır Gazi Yaşargil Training and Research Hospital, which functions as a tertiary cancer treatment facility.
Between March 2025 and December 2025, patients with newly diagnosed clinical early stage (FIGO 2023 stages 1 and 2) endometrial cancer who will be treated with laparoscopic surgical staging with SLN mapping at our institution will be randomized into groups. The research procedure has been approved by the ethics committee/institutional review board of Diyarbakır Gazi Yaşargil Training and Research Hospital and signed by the patient will be included in each table reviewed.
Eligible participants will be required to give informed consent to participate in the study.
Inclusion criteria will include
Exclusion criteria will include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgical Procedure of transvaginal sentinel lymphadenectomy group: All patients will be operated in accordance with Memorial Sloan Kettering Cancer Center procedure. V-NOTES will consist of transvaginal paracervical sentinel lymph node (SLN) mapping followed by V-NOTES hysterectomy and bilateral salpingo-oophorectomy (BSO). SLN Mapping: Under general anesthesia, subjects will be placed in supine lithotomy position. Methylene blue solution (BLUMET IV INJECTION INJECTABLE 50 mg/5 ml 1x5 ml) (1 mL submucosal to the cervix at the 3 and 9 o'clock positions and 1 mL at a depth of 1-2 cm, using a total volume of 2-4 mL. Monitoring of lymphatic ducts includes identification of structures stained with methylene blue dye in the expected anatomical location, typically between the internal and external iliac veins or in the obturator region. Bilateral and symmetrical structures believed to be sentinel lymph nodes (SLNs) will be removed. When unilate
Procedure: Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy
In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with methylene blue injection for sentinel lymph nodes. Methylene blue will be injected at the 3 and 9 o'clock positions on the cervix, first at a depth of 1 mm and then at 4 mm, with 1 cc administered at each point. This will result in a total of 4 cc (1 cc x 4). Then, the procedure will continue with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.
Procedure: Transperitoneal lymphadenectomy
The procedure begins with a vaginal incision in the lateral vaginal fornices (on both sides), which is then extended to allow placement of the V-NOTES apparatus. By identifying an appropriate cleavage plane, the obturator fossa is accessed to excise the obturator lymph nodes. Following this, an anterior colpotomy is performed to access the vesicocervical space, and a posterior colpotomy is made to open the rectouterine pouch. The V-NOTES apparatus is then placed to continue with the hysterectomy and bilateral salpingo-oophorectomy (BSO).
In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.
Total operation duration
The total duration of the operation in minutes
Time frame: During surgery
Duration of right and left lymphadenectomy
The duration of lymphadenectomies in minutes
Time frame: During surgery
Number of lymph nodes excised
Lymph node count in the pathology report
Time frame: Postoperative second week
number of positive lymph nodes
Sentinel positive lymph nodes in the pathology report
Time frame: Postoperative second week
Hospitalization duration
Number of days patients stayed at the hospital postoperatively
Time frame: During hospital stay
Total bleeding volume
Measured by the suction bottle's volume and number of surgical gauzse used during surgery
Time frame: During surgery
Difference between pre- and postoperative hemoglobin values
Hemoglobin level (g/dL)
Time frame: Postoperative 1st day
Surgical complications
Clavien dindo scale of surgical complications
Time frame: During hospital stay
Location o SLN
The area that sentinel lymph node detected internal iliac, external iliac ,bifurcation or obturator fossa
Time frame: During surgery
Preoperative and postoperative hematocrit values
Hematocrit level (%)
Time frame: During hospital stay
Tumor's patological features
Histophatology, grade, lymphovascular invasion, tumor diameter(cm), myometrial invasion, stage, total positive lymph node count
Time frame: Postoperative second week
Management of complications
intraoperative and postoperative complication's management
Time frame: through study completion
Duration of lateral colpotomy
at transvaginal retroperitoneal procedure ; before the lymphadenectomy we are making and incision to the lateral of cervix .this time describes the time that to reach the obturator fossa to pick the nodes.
Time frame: During surgery
Duration of hysterectomy
minutes
Time frame: During surgery
Sentinel lymphnode's side and number
number
Time frame: Postoperative second week
Postoperative pain
visual analogue scale, higher scores indicate worse pain
Time frame: 3rd and 6th month after operation
Sexual function
assessed by Female Sexual Function Index, higher scores indicate greater satisfaction
Time frame: at postoperative 3rd and 6th month
Timing of passing gas
Bowel function
Time frame: During hospital stay
Demographic features
Age, gravidity, parity, previous vaginal delivery, body-mass index
Time frame: Postoperative second week
Previous abdominal surgery
Medical history
Time frame: Preoperative day
Initiation of mobilization
After operation the time (hour) that paient is avaliable to mobilize out from the bed
Time frame: During hospital stay
6th hour and 24th hour VAS score
The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."
Time frame: postoperatively 6th and 24th hours score
Plan to share: Yes — All IPD that underlie results in a publication will be shared.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: It will be shared when the study is published.
Access criteria: When the study is published, the data will be shared by the corresponding author on request.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.
Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 9 months is below that.
Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital